Catalogs from Navinci Diagnostics
Naveni™ CD8/MHC-I Atto647N - Navigate Immune Responses in situ
Dive into the secrets of immune responses with Navinci's CD8/MHC-I in situ proximity ligation assay for the detection of CD8/MHC-I interactions, providing a nuanced perspective for a detailed and accurate portrayal of the immune response. This deeper understanding becomes the cornerstone for developing targeted immunotherapies, marking a potential leap forward in precision medicine for cancer treatment. Navinci has now developed the first commercial in situ proximity ligation assay for the specific detection of CD8/MHC-I interactions. Released February 2024.
NaveniFlex™ Cell - Elevate Your Research
Since diverse sample types demand tailored treatment, our partner Navinci Diagnostics has optimized their flexible offering, aligning it even more closely with your needs. NaveniFlexTM Cell is based on the company's NaveniTM proximity ligation technology and is specifically optimized for studying protein-protein interactions and protein interplay in cell samples. It allows you to analyze even the most low-abundance protein targets with high precision and to obtain easily quantifiable data. The protocol is more than 60 minutes faster than the previous kits and it is also compatible with 96-well plates for high throughput screening. Released September 2023.
Naveni™ PD1/PD-L1 Atto647N - Illuminate PD1/PD-L1 Interactions
Unlock the potential of immune checkpoint inhibition therapy with the newest product by Navinci Diagnostics: NaveniTM PD1/PD-L1 Atto647N, the pioneering fluorescent assay for in situ detection of PD1/PD-L1 interactions. Use this assay to identify PD1/PD-L1 interactions with exceptional specificity and to visualize PD1/PD-L1 in the tumor microenvironment. Enhance the understanding of signaling pathways in the context of immune checkpoint blockade and uncover the diagnostic potential of the PD1/PD-L1 interaction. Released July 2023.
NaveniLink™ - Expanding your Options
Would you like to conjugate your own primary antibodies for using them in proximity ligation assays? The NaveniLink conjugation kit by Navinci Diagnostics allows you to do just that. You can use your primary antibodies and easily conjugate them with Navinci's proprietary oligonucleotide sequences. These conjugates can be used with the Naveni® flexible product line, which includes NaveniFlex Cell, NaveniFlex Tissue, and NaveniBright. NaveniLink offers a practical solution to enhance your research capabilities. Released April 2023.
NaveniFlex™ Tissue - An eye-opening Solution for Tissue Samples
Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced NaveniTM proximity ligation technology developed by Navinci Diagnostics for NaveniFlexTM Tissue kits is tailor-made to overcome common background challenges in tissue samples. The kits are optimized to deliver highly reproducible and accurate results even for the least abundant protein interactions. NaveniFlexTM Tissue is an eye-opening solution for your tissue samples. Released January 2023.
Naveni™ TriFlex Cell - Discover the Secret Life of Proteins
Ever wished there was a way to take a snapshot of two proteins as they interact or remain unbound? The door to studying protein interplay and functional states while retaining the structural integrity of the cell is now open! Find out about protein complex formation and disassembly in response to different stimuli in situ with the help of Navinci's latest innovation. Naveni™ TriFlex Cell is a revolutionary proximity-based technology that can concurrently visualize two proteins in a free and complex state in any cell compartment. It aids you in elucidating the spatiotemporal communication between proteins in their native environment. With Naveni™ TriFlex Cell, you can detect the relative amounts of total protein A, total protein B, and the interaction AB between the two proteins. Understanding the relationship between your favorite proteins has never been easier! Released January 2023.
Naveni™ PD1/PD-L1 - Detect PD1/PD-L1 Interactions in situ
Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed. PD-L1 IHC is commonly used as a biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear. Navinci Diagnostics has now developed the first commercial Proximity Ligation Assay for the specific detection of PD1/PD-L1 interactions in situ. Released September 2022.
NaveniBright™ - BRINGING PRECISION TO SPATIAL PROTEOMICS
In situ detection of protein-protein interactions and post-translational modifications: The NaveniBrightTM is a new Naveni product line with chromogenic readout. The in situ kits are based on the proprietary NaveniTM Proximity Ligation Technology. The assay significantly enhances the chromogenic signal, providing a stronger and more accurate staining of cell or tissue samples. Released May 2022.